Research and Markets: Partnering in the Global Generics Industry 2010 - A Guide to Companies

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/4331a3/partnering_in_the) has announced the addition of the "Partnering in the Global Generics Industry 2010 - A Guide to Companies" report to their offering.

"Facts, statistics and insights on 168 medium-sized generic manufacturers from 40 countries

The operating environment for generics companies is changing rapidly as the industry matures and growth focuses on new market opportunities.

The current economic downturn has impacted the sector in terms of the number and types of deal but consolidation continues to affect the market, with a smaller number of big players dominating.

Acquisition is still a favoured route to fast market access but strategic partnering is on the rise. In such a market you need to know:

  • Who are the medium-sized companies of note?
  • How well do they perform?
  • What drugs do they produce?
  • Where are they located?

This report will tell you!

Consolidation and collaboration runs throughout the generic industry. Here's just a taste of the acquisitions, controlling investments and deals reported recently:

  • URL Pharma acquire manufacturing assets of PharmPro
  • Luitpold Pharma acquires Pharmaforce
  • Hi-Tech Pharmacal acquires product line from Blaine Company
  • Aspen Pharmacare acquires Sigmas pharmaceutical division
  • Sun Pharmaceuticals long expected acquisition of Taro Pharmaceuticals
  • Sandoz acquires Ebewe Pharmaceuticals
  • GSK acquires Stiefel
  • Strides Arcolab acquires Ascent Pharmahealth
  • sanofi-aventis form Japanese joint venture with Nichi-Iko
  • Adcock-Ingram acquires Ghanaian manufacturer Ayrton
  • Cephalon acquires Mepha
  • Strategic partnering

In addition to outright purchase, strategic partnering or the acquisition of specific drug assets is on the rise as companies seek to bring lower costs and focus to their portfolios. With business cycles growing shorter and shorter, market entry is quicker, more reliable and less risky through acquisition and partnering.

The fundamental market drivers are sound

In addition to ongoing expansion, there are other drivers which are causing the generic companies to consider the future:

  • Over the next 5 years a number of blockbuster pharmaceutical products such as Lipitor, Cozaar, Lovenox, Plavix, Cymbalta and Seroquel will be losing patent protection.
  • The number of biologics coming into the remit of generic companies is increasing, raising interest in companies with biosimilars production capability.
  • The branded industrys response

The branded industry continues to vigorously protect its IP and maximise the lifetime value of its products. While legal initiatives will remain a key weapon there will also be commercial responses such as issuing early branded generics, collaborative working with a limited number of generic producers, new formulations or combination products.

Over 150 companies covered in this report from around the world.

To view all companies covered and for more information, please visit http://www.researchandmarkets.com/research/4331a3/partnering_in_the

Source: Espicom Business Intelligence Ltd



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.